The promise of anti-inflammatory therapies for CNS injuries and diseases

References

• Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo.Science308(5726), 1314–1318 (2005).
   PubMed Web of Science ®Google Scholar
• Rivest S. Regulation of innate immune responses in the brain. Nat. Rev. Immunol.9(6), 429–439 (2009).
   PubMed Web of Science ®Google Scholar
• Allan SM, Rothwell NJ. Cytokines and acute neurodegeneration. Nat. Rev. Neurosci.2(10), 734–744 (2001).
   PubMed Web of Science ®Google Scholar
• Allan SM, Tyrrell PJ, Rothwell NJ. Interleukin-1 and neuronal injury. Nat. Rev. Immunol.5(8), 629–640 (2005).
   PubMed Web of Science ®Google Scholar
• Glezer I, Simard AR, Rivest S. Neuroprotective role of the innate immune system by microglia. Neuroscience147(4), 867–883 (2007).
   PubMedGoogle Scholar
• Nguyen MD, Julien JP, Rivest S. Innate immunity: the missing link in neuroprotection and neurodegeneration? Nat. Rev. Neurosci.3(3), 216–227 (2002).
   PubMed Web of Science ®Google Scholar
• Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat. Med.12(9), 1005–1015 (2006).
   PubMed Web of Science ®Google Scholar
• Wyss-Coray T, Mucke L. Inflammation in neurodegenerative disease – a double-edged sword. Neuron35(3), 419–432 (2002).
   PubMed Web of Science ®Google Scholar
• Arnett HA, Mason J, Marino M, Suzuki K, Matsushima GK, Ting JP. TNFα promotes proliferation of oligodendrocyte progenitors and remyelination. Nat. Neurosci.4(11), 1116–1122 (2001).
   PubMed Web of Science ®Google Scholar
• Herx LM, Rivest S, Yong VW. Central nervous system-initiated inflammation and neurotrophism in trauma: IL-1β is required for the production of ciliary neurotrophic factor. J. Immunol.165(4), 2232–2239 (2000).
   PubMedGoogle Scholar
• Mason JL, Suzuki K, Chaplin DD, Matsushima GK. Interleukin-1β promotes repair of the CNS. J. Neurosci.21(18), 7046–7052 (2001).
   PubMed Web of Science ®Google Scholar
• Turrin NP, Rivest S. Tumor necrosis factor α but not interleukin 1β mediates neuroprotection in response to acute nitric oxide excitotoxicity. J. Neurosci.26(1), 143–151 (2006).
   PubMed Web of Science ®Google Scholar
• Boivin A, Pineau I, Barrette B et al. Toll-like receptor signaling is critical for Wallerian degeneration and functional recovery after peripheral nerve injury. J. Neurosci.27(45), 12396–12406 (2007).
   PubMedGoogle Scholar
• Kigerl KA, Lai W, Rivest S, Hart RP, Satoskar AR, Popovich PG. Toll-like receptor (TLR)-2 and TLR-4 regulate inflammation, gliosis, and myelin sparing after spinal cord injury. J. Neurochem.102(1), 37–50 (2007).
   PubMed Web of Science ®Google Scholar
• Kilic U, Kilic E, Matter CM, Bassetti CL, Hermann DM. TLR-4 deficiency protects against focal cerebral ischemia and axotomy-induced neurodegeneration. Neurobiol. Dis.31(1), 33–40 (2008).
   PubMed Web of Science ®Google Scholar
• Tang SC, Lathia JD, Selvaraj PK et al. Toll-like receptor-4 mediates neuronal apoptosis induced by amyloid β-peptide and the membrane lipid peroxidation product 4-hydroxynonenal. Exp. Neurol.213(1), 114–121 (2008).
   PubMed Web of Science ®Google Scholar
• Wang Q, Tang XN, Yenari MA. The inflammatory response in stroke. J. Neuroimmunol.184(1–2), 53–68 (2007).
   PubMed Web of Science ®Google Scholar
• Liesz A, Suri-Payer E, Veltkamp C et al. Regulatory T cells are key cerebroprotective immunomodulators in acute experimental stroke. Nat. Med.15(2), 192–199 (2009).
   PubMed Web of Science ®Google Scholar
• Reynolds AD, Stone DK, Hutter JA, Benner EJ, Mosley RL, Gendelman HE. Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson’s disease. J. Immunol.184(5), 2261–2271 (2010).
   PubMed Web of Science ®Google Scholar
• Combarros O, Infante J, Rodriguez E et al. CD14 receptor polymorphism and Alzheimer’s disease risk. Neurosci. Lett.380(1–2), 193–196 (2005).
   PubMedGoogle Scholar
• Liu Y, Walter S, Stagi M et al. LPS receptor (CD14): a receptor for phagocytosis of Alzheimer’s amyloid peptide. Brain128(Pt 8), 1778–1789 (2005).
   PubMedGoogle Scholar
• Chen K, Iribarren P, Hu J et al. Activation of Toll-like receptor 2 on microglia promotes cell uptake of Alzheimer disease-associated amyloid β peptide. J. Biol. Chem.281(6), 3651–3659 (2006).
   PubMed Web of Science ®Google Scholar
• Richard KL, Filali M, Prefontaine P, Rivest S. Toll-like receptor 2 acts as a natural innate immune receptor to clear amyloid β 1–42 and delay the cognitive decline in a mouse model of Alzheimer’s disease. J. Neurosci.28(22), 5784–5793 (2008).
   PubMed Web of Science ®Google Scholar
• Tahara K, Kim HD, Jin JJ, Maxwell JA, Li L, Fukuchi K. Role of Toll-like receptor signalling in Aβ uptake and clearance. Brain129(Pt 11), 3006–3019 (2006).
   PubMed Web of Science ®Google Scholar
• Scholtzova H, Kascsak RJ, Bates KA et al. Induction of Toll-like receptor 9 signaling as a method for ameliorating Alzheimer’s disease-related pathology. J. Neurosci.29(6), 1846–1854 (2009).
   PubMed Web of Science ®Google Scholar
• Fiala M, Liu PT, Espinosa-Jeffrey A et al. Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimer’s disease patients are improved by bisdemethoxycurcumin. Proc. Natl Acad. Sci. USA104(31), 12849–12854 (2007).
   PubMed Web of Science ®Google Scholar
• Ray S, Britschgi M, Herbert C et al. Classification and prediction of clinical Alzheimer’s diagnosis based on plasma signaling proteins. Nat. Med.13(11), 1359–1362 (2007).
   PubMed Web of Science ®Google Scholar
• Majumdar A, Cruz D, Asamoah N et al. Activation of microglia acidifies lysosomes and leads to degradation of Alzheimer amyloid fibrils. Mol. Biol. Cell18(4), 1490–1496 (2007).
   PubMed Web of Science ®Google Scholar
• Boissonneault V, Filali M, Lessard M, Relton J, Wong G, Rivest S. Powerful beneficial effects of macrophage colony-stimulating factor on β-amyloid deposition and cognitive impairment in Alzheimer’s disease. Brain132(Pt 4), 1078–1092 (2009).
   PubMedGoogle Scholar
• Martin BK, Szekely C, Brandt J et al. Cognitive function over time in the Alzheimer’s Disease Anti-Inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch. Neurol.65(7), 896–905 (2008).
   PubMed Web of Science ®Google Scholar